Artigo
Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia
Fecha
2005-03-01Registro en:
American Journal of Hematology. Hoboken: Wiley-liss, v. 78, n. 3, p. 243-244, 2005.
0361-8609
10.1002/ajh.20293
WOS:000227412900015
Autor
Vicari, Perla [UNIFESP]
Mello, Adriana Barretto de [UNIFESP]
Figueiredo, Maria Stella [UNIFESP]
Institución
Resumen
Fetal hemoglobin (HbF) inhibits the polymerization of sickle hemoglobin, modulating the clinical features of sickle cell anemia (SCA). Hydroxyurea (HU) therapy can increase the HbF level, although its production can be influenced by genetic determinants. Twenty-two Brazilian SCA patients were evaluated over 5 years before and after HU use. We analyzed (1) beta(S) haplotype; (2) patient characteristics; and (3) toxicity. No differences between age, sex, and HU response were observed. We found 40.9% of homozygous for Bantu haplotype, and, in contrasting to other trials, we observed HbF level increase in this group (3.84-9.08 g/dL, P = 0.003). Adverse effects were rare. Labyrinthitis was observed in 2 (9.10%) patients after HU use, although this complication had not been described before.